Lenvima Now Available Through Specialty Pharmacies

Lenvima Approved for RAI-Refractory Differentiated Thyroid Cancer
Lenvima Approved for RAI-Refractory Differentiated Thyroid Cancer

Eisai announced that Lenvima (lenvatinib) is now available through two specialty pharmacies, Accredo and Biologics Inc. for the treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC).

Lenvatinib is an oral receptor tyrosine kinase inhibitor with a unique binding mode that selectively inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors, in addition to other proangiogenic and oncogenic pathway-related tyrosine kinases thought to be involved in tumor proliferation.

RELATED: Lenvima Approved for RAI-Refractory Differentiated Thyroid Cancer

Lenvima is available as 4mg and 10mg strength capsules in a carton of six 5-day blister cards.

For more information call (888) 422-4743 or visit Eisai.com.

Loading links....